DB-1303 (also known as BNT323) for HER2-positive advanced solid tumors (cancers that have spread and express HER2, a protein that promotes cancer growth)
DualityBio Inc.· DB-1303/BNT323 Phase 1/2a Study
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT05150691 on ClinicalTrials.gov →Study type
interventional
Design
Open-label, multicenter, first…
Target enrollment
796
Est. completion
2027-08
Investor scorecard
Probability of success
moderate
Timeline to catalyst
Interim data may be released as early as 2024-2025, with final completion expected in 2027. Investors should watch for dose-escalation results, safety updates, and early efficacy signals from dose expansion cohorts.
Potential stock impact
SignificantThe drug is in early Phase 1/2a, and the probability of eventual approval is low (typically around 10-20% for oncology drugs from Phase 1). However, the mechanism is promising, and the HER2-targeted ADC space has seen successes. The trial's large enrollment (796) suggests the sponsors are confident, but safety and efficacy data are still unknown. Competition from Enhertu is strong, so differentiation will be key. The probability is moderate because there is a reasonable chance of showing activity, but many hurdles remain.
What is being tested?
DB-1303 (also called BNT323) is an experimental drug for patients with advanced cancers that have a specific marker called HER2 on their surface. HER2 is a protein that can promote cancer growth. This drug is a type of antibody-drug conjugate (ADC), which acts like a guided missile: it binds to HER2 on cancer cells and delivers a toxic payload directly inside them, sparing normal cells. The trial is testing the drug's safety, tolerability, and preliminary effectiveness in patients with various solid tumors (like breast, lung, or stomach) that have spread and have not responded to standard treatments. It's a first-in-human study, meaning this is the first time the drug is given to people.
How does the trial work?
The trial is divided into two parts. In Phase 1 (dose escalation), small groups of patients receive increasing doses of DB-1303 to find the highest dose that is safe (maximum tolerated dose) and to determine the recommended dose for Phase 2. In Phase 2 (dose expansion), more patients receive that recommended dose to further evaluate safety and see how well it shrinks tumors. The study is open-label, meaning both doctors and patients know they are getting the drug. It is not randomized; all patients get the active drug. Some patients in a specific expansion cohort (Dose Expansion 10) will also receive ritonavir or itraconazole (drugs that affect liver enzymes) to see how they affect the levels of DB-1303 in the body, which helps understand drug interactions. Patients are monitored regularly with blood tests, imaging scans, and physical exams to track side effects and tumor response.
What does success look like?
Success in Phase 1 is primarily about safety: finding a dose that causes manageable side effects. In Phase 2, the key measure is objective response rate (ORR) - the percentage of patients whose tumors shrink by at least 30% or disappear completely. For advanced cancers that have failed multiple treatments, an ORR of 20-30% is often considered promising, but for HER2-positive tumors, higher responses (like 40-60%) are seen with other ADCs like Enhertu. The trial will also look at duration of response, progression-free survival, and overall survival as secondary measures, though these are not primary endpoints. If the drug shows a good safety profile and meaningful tumor shrinkage, it would support further development in later-phase trials.
What it means for investors
For investors, this trial is an early-stage signal of whether DB-1303 could become a competitor in the HER2-targeted cancer market. Positive safety and efficacy data could boost the stock of DualityBio (and its partner BioNTech, which is co-developing the drug). If the drug shows strong responses in patients who have failed Enhertu or Kadcyla, it could capture a significant share of the HER2-positive solid tumor market, which is worth billions. However, early-phase data can be misleading; many drugs fail in later trials. Investors should watch for dose-limiting toxicities, especially lung toxicity (common with ADCs), and the overall response rate in heavily pretreated patients. A favorable risk/benefit profile could lead to accelerated approval pathways, while any safety red flags could sink the program. The trial is expected to complete by 2027, but interim data may be released earlier, providing catalysts.
Trial endpoints
Primary endpoints
Secondary endpoints
Competitive landscape
HER2-positive cancers include breast, gastric, lung, and colorectal cancers, among others. The global market for HER2-targeted therapies is estimated to exceed $10 billion annually, driven by drugs like Herceptin, Perjeta, Kadcyla, and Enhertu. Despite existing options, there remains a high unmet need for patients who progress on current ADCs or develop resistance. DB-1303 aims to offer a potentially safer or more effective alternative, especially in tumors beyond breast and gastric cancers. If approved, it could capture a portion of this market, particularly if it demonstrates activity in Enhertu-resistant patients or in HER2-low expressing tumors.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Trastuzumab deruxtecan (Enhertu) | Daiichi Sankyo and AstraZeneca | Phase 1 | Already approved for HER2-positive breast and gastric cancers; has shown high response rates but carries a risk of interstitial lung disease. |
| Trastuzumab emtansine (Kadcyla) | Roche | Phase 1 | Approved for HER2-positive breast cancer; an older ADC with a different payload, but less effective than Enhertu in some settings. |
| Trastuzumab duocarmazine (SYD985) | Byondis | Phase 1 | Another HER2-targeting ADC with a different payload; in Phase 3 for HER2-positive breast cancer, but has shown ocular toxicity. |
| ARX788 | Ambrx | Phase 1 | A site-specific HER2 ADC with a stable linker; in Phase 2 for HER2-positive breast cancer, but development has faced setbacks. |
Historical context
Prior trial results
This is a first-in-human trial, so there are no prior clinical results for DB-1303 in humans. Preclinical studies have shown that DB-1303 has potent antitumor activity in HER2-positive cell lines and animal models, with a favorable safety profile compared to other ADCs.
Regulatory history
No regulatory designations (like fast track or breakthrough) have been publicly announced for DB-1303. The trial is being conducted under an IND (Investigational New Drug) application. The drug is being developed in collaboration with BioNTech, which may bring additional expertise in immunotherapy.
Similar drug precedents
The success of Enhertu (trastuzumab deruxtecan) has validated the ADC approach for HER2-positive cancers. Enhertu showed remarkable response rates in heavily pretreated patients, leading to accelerated approvals. However, it also highlighted the risk of interstitial lung disease, a potentially fatal side effect. Kadcyla, an earlier ADC, has been less effective but has a better safety profile. These precedents suggest that a new HER2 ADC must demonstrate a favorable benefit-risk balance to compete. If DB-1303 can show high efficacy with lower lung toxicity, it could become a preferred option.